ACTION: Antidiuresis using vasopressin-V2-receptor agonists as treatment of incontinence

• Research unit: EU RFP
• Project number: 02.0438

Key words (English)

Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management

Research programs (English)

EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'

Short description (English)

See abstract

Further information (English)

Full name of research-institution/enterprise:
Universität Basel
Biozentrum, C-CINA, WRO-1058.P.24
Maurice E. Müller Institute for Structural Biology, c/o Syngenta AG

Abstract (English)

More than forty million middle-aged and elderly EU-citizens suffer from urinary voiding disorders, including incontinence and frequent nightly urination, due to multi factorial diseases. The overall goal is to establish temporary antidiuresis as an efficient new therapeutic strategy to improve health and quality of life.
This will be based on extensive basic, clinical and industrial research of vasopressin-V_2-receptors (VP-V_2R) and kidney function. As necessary new drugs, short-acting VP-V_2R agonists will be developed.
Lead compounds exist and test systems will be established to characterise the compounds at the molecular structural level and at the cellular and integrated level. After safety, testing lead compounds will be used in initial clinical trials. Such a treatment will provide symptom relief for the sever common life disrupting disorders with improved health and life quality for this very large group of patients.

References in databases (English)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 02.0438